<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intraatrial reentrant tachycardia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intraatrial reentrant tachycardia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intraatrial reentrant tachycardia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Munther K Homoud, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Lévy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrial tachycardias have traditionally been characterized as automatic, triggered, or reentrant. However, the European Society of Cardiology and the North American Society of Pacing and Electrophysiology in 2001 proposed a classification that takes into consideration both anatomic features and electrophysiologic mechanisms [<a href="#rid1">1</a>]. Atrial tachycardia is the overriding term that includes two major categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Focal atrial tachycardia due to an automatic, triggered, or microreentrant mechanism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Macroreentrant atrial tachycardia, including typical atrial flutter and other well-characterized macroreentrant circuits in the right and left atrium.</p><p></p><p>Intraatrial reentrant tachycardia (IART) falls into the latter group. Furthermore, the joint American College of Cardiology/American Heart Association/Heart Rhythm Society 2015 guidelines further defined macroreentrant atrial tachycardias that do not involve the tricuspid valve isthmus as "atypical or non-cavo-tricuspid isthmus-dependent atrial flutter" [<a href="#rid2">2</a>]. These macroreentrant supraventricular tachycardias often involve the left atrium, particularly after atrial fibrillation (AF) ablation or Maze surgery for AF. They may involve any atrium where a scar, surgical or catheter-induced, may have taken place. This topic will discuss the mechanisms, clinical manifestations, and treatment of IART. Discussions of other specific atrial arrhythmias are presented separately. (See  <a class="medical medical_review" href="/d/html/900.html" rel="external">"Focal atrial tachycardia"</a> and  <a class="medical medical_review" href="/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)"</a> and  <a class="medical medical_review" href="/d/html/1048.html" rel="external">"Overview of atrial flutter"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION, PREVALENCE, AND MECHANISMS</span><span class="headingEndMark"> — </span>Intraatrial reentrant tachycardia (IART) refers to any macroreentrant atrial tachycardia that does not utilize the cavotricuspid isthmus  (<a class="graphic graphic_figure graphicRef52904" href="/d/graphic/52904.html" rel="external">figure 1</a>) as a critical pathway for the reentry to perpetuate. IART generally occurs in one of three settings: post-surgical repair of congenital heart disease (incidence of 16 to 50 percent post Fontan procedure, 15 to 48 percent post Mustard or Senning procedures, 12 to 34 percent post Tetralogy of Fallot repair), post-surgical scar (incisional tachycardia), or post catheter based or surgical management of atrial fibrillation (AF) [<a href="#rid3">3,4</a>]. With the increase in AF ablation, an increase in IART is arising due to the surgical maze and catheter based procedures in the left atrium. IART has also been reported in the absence of surgical or catheter intervention [<a href="#rid5">5</a>].</p><p>Reentry refers to a circuit in which previously excited tissue is re-excited, producing an extra beat or a sustained rhythm. Sinoatrial (SA) nodal reentrant tachycardia and IART (also called reentrant atrial tachycardia) are the two major types of paroxysmal reentrant supraventricular tachycardias in which the reentrant circuit does not involve the atrioventricular (AV) node or accessory pathways  (<a class="graphic graphic_figure graphicRef82249" href="/d/graphic/82249.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)"</a>.)</p><p>Reentry pathways are usually defined by the following characteristics: </p><p class="bulletIndent1"><span class="glyph">●</span>Two discrete but connected pathways.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Slow conduction in one of the pathways and unidirectional block in the other pathway.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Block in the pathway with unidirectional block following a premature beat, with conduction through the slower pathway allowing the pathway with unidirectional block to recover conduction and conduct the impulse back to the first pathway, hence initiating reentry.</p><p></p><p>Block may be anatomical (accessory bypass tract, slow or fast AVN pathway), functional (ischemia, electrolyte imbalance or anti arrhythmic agents), or both.</p><p>IART has a different activation sequence of atrial depolarization, leading to a P wave morphology that differs from that of normal sinus rhythm. In comparison, SA nodal reentrant tachycardia has an activation sequence similar to that of normal sinus rhythm so that the P waves on the surface ECG appear to be normal. Only the abrupt onset and termination of this arrhythmia distinguish it clinically from sinus tachycardia. (See <a class="local">'Electrophysiological features'</a> below and  <a class="medical medical_review" href="/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)"</a>.) </p><p>IART was responsible for approximately 6 percent of atrial tachycardias in patients referred for electrophysiologic studies to an active electrophysiologic group [<a href="#rid6">6</a>]. Organic heart disease is common in adults with this arrhythmia. In children, intraatrial tachycardia is often associated with surgery that involves the atrium, such as the repair of an atrial septal defect or correction of transposition [<a href="#rid7">7</a>], but may occur with any repair that includes an atrial scar. IART may be quite detrimental because of the elevated heart rate and the frequent loss of normal AV synchrony. It has been suggested that there is an increased rate of right and atrial thrombosis with IART.</p><p>The other group of patients in whom IART is seen is individuals who have undergone catheter or surgical ablation for AF. The incidence varies between 2.9 percent following pulmonary vein isolation (PVI) and 31 percent following circumferential ablation associated with creation of linear lesions [<a href="#rid8">8,9</a>]. Within this group of patients, reentrant tachycardia either exists as a macro- or microreentrant tachycardia. Microreentrant tachycardias are usually seen at sites of pulmonary vein reconnection following PVI for AF. Gaps in linear lesions formed for ablation of persistent or long-standing persistent AF promote the emergence of reentrant atrial tachyarrhythmias. These arrhythmias are often less well tolerated than the AF that prompted the ablation in the first place. They are often seen around the mitral valve (peri-mitral), in the atrium roof, or, less commonly, the septum. The cavotricuspid isthmus is not uncommonly involved. Studies have shown no added advantage to the creation of these lesions [<a href="#rid10">10</a>]. Society guidelines dissuade creation of these lines, confining them only to cases where IARTs are encountered [<a href="#rid11">11</a>]. Focal IARTs are eliminated by isolating the reconnected pulmonary vein. </p><p>IART most often begins with an premature atrial complex (PAC; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat) that tends to occur quite early [<a href="#rid6">6,12-14</a>]. The initiating beat may arise in either atrium, and an intraatrial conduction delay is necessary for the induction and maintenance of the arrhythmia. Ventricular premature beats very rarely initiate intraatrial reentrant tachycardia, and, if they do, it is usually due to rapid retrograde conduction through an accessory bypass tract, which results in the early prematurity usually required to initiate reentry [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H13989262"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations and significance of intraatrial reentrant tachycardia (IART) are variable, depending upon the hemodynamic effects of the increase in heart rate and the heart rate achieved. Some patients are asymptomatic, while others have symptoms that range from palpitations and lightheadedness to, in rare cases, syncope. If a patient is examined during an episode of arrhythmia, they will have a regular heart rate greater than 100 beats per minute.</p><p>Most episodes of IART do not precipitate hemodynamic compromise or limiting symptoms. However, higher ventricular rates associated with IART in a patient with underlying advanced cardiac or pulmonary disease can sometimes exacerbate their disease, leading to signs and symptoms of angina, heart failure, or worsening systemic oxygenation.</p><p>In the face of persistently elevated ventricular rates (eg, for weeks to months), particularly if baseline ventricular dysfunction exists, heart failure (tachycardia-mediated cardiomyopathy) may ensue. The atrial rates tend to be slower than the atrial rates in isthmus dependent atrial flutter, allowing 1:1 conduction from the atria to the ventricles and, subsequently, more potentially detrimental hemodynamic effects [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H13989352"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of intraatrial reentrant tachycardia (IART) should be considered in the presence of a regular but rapid pulse and heartbeat on physical examination. The diagnosis cannot be confirmed, however, without an electrocardiogram or, in most cases, invasive electrophysiologic studies.</p><p>The suspicion for IART rests on the patient's history combined with the electrocardiogram. A patient with a cardiac surgical history, particularly for correction of a congenital heart defect, presenting with what looks like atrial flutter should be considered to suffer from IART. Like other reentrant tachycardias, the onset is sudden, and vagal maneuvers may help slow the ventricular rate but will not change the atrial rate.</p><p class="headingAnchor" id="H3"><span class="h2">Electrocardiographic findings</span><span class="headingEndMark"> — </span>During an arrhythmic episode, the electrocardiographic (ECG) findings in IART are similar to those of most other regular supraventricular tachycardias (SVT), with evidence of atrial activity (P waves) associated with ventricular activity (QRS complexes) in a 1:1 fashion. In the appropriate clinical setting (eg, prior cardiac surgery, prior ablation, etc), the surface ECG can be highly suggestive of IART. However, the surface ECG alone cannot reliably distinguish between IART and other types of SVT, most notably focal atrial tachycardia. (See <a class="local">'Electrophysiological features'</a> below and <a class="local">'Differential diagnosis'</a> below.)</p><p>As noted above, P wave morphology in IART is different from that in normal subjects due to a difference in the activation sequence of atrial depolarization. The sequence depends upon the reentrant circuit  (<a class="graphic graphic_figure graphicRef52904" href="/d/graphic/52904.html" rel="external">figure 1</a>) which, in turn, may involve an anatomical obstacle or result from functional changes in refractoriness. (See <a class="local">'Definition, prevalence, and mechanisms'</a> above.)</p><p>Clinically, the P wave morphology in aVL and V1 are useful clues in identifying the site of origin of the arrhythmia. A positive P wave in V1 and a negative P wave in aVL suggest a left atrial origin  (<a class="graphic graphic_waveform graphicRef73578" href="/d/graphic/73578.html" rel="external">waveform 1</a>), while a negative P wave in V1 and a positive P wave in aVL suggests a right atrial origin. These changes reflect the vectorial sequence. The left atrium is posterior and to the left, so the sequence of the activation for an impulse arising in the left atrium usually is anterior towards V1 (leading to a positive P wave) and rightward away from aVL (leading to a negative P wave); the sequence is reversed with a right atrial origin. Both reentrant and automatic atrial tachycardias will show these morphologies.</p><p>However, the electrocardiogram can be misleading in non-isthmus dependent macro reentrant tachycardias, particularly after catheter ablation for atrial fibrillation where the index of suspicion is always high that the atrial tachyarrhythmia is left sided [<a href="#rid16">16</a>]. Counterclockwise isthmus dependent atrial flutter characteristically displays upright flutter waves in V1 and negative flutter waves in leads II, III, and aVF. If the isthmus dependent flutter is clockwise, leads II, III, and aVF will display upright flutter waves. V1 will remain upright as well. Any departure from this pattern, particularly in the appropriate setting (postsurgical procedure, catheter, or surgical ablation) should lead one to suspect a nonisthmus dependent IART. Left sided IART can display similar electrocardiographic findings. (See  <a class="medical medical_review" href="/d/html/1061.html" rel="external">"Electrocardiographic and electrophysiologic features of atrial flutter"</a>.)</p><p class="headingAnchor" id="H1013571688"><span class="h2">Electrophysiological features</span><span class="headingEndMark"> — </span>Clinically, it is important to distinguish intraatrial reentrant tachycardia (IART) from other supraventricular tachycardias (SVT), particularly focal atrial tachycardia. Since the surface electrocardiogram alone is not reliable in distinguishing IART from other types of SVT, invasive electrophysiologic studies (EPS) are employed to help make this distinction. Since macroreentrant atrial arrhythmias, including IART, are reentrant, they can be entrained during EPS with manifest and concealed fusion, and upon cessation of atrial pacing, the post pacing interval should be within 30 milliseconds of the tachycardia cycle length. The use of newer mapping techniques such as electroanatomic mapping further helps to make this distinction where focal mechanisms display centrifugal activation patterns, reentry displays an "early meets late", and the entire cycle length of the tachycardia can be mapped to the chamber containing the tachycardia. (See  <a class="medical medical_review" href="/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a>.)</p><p>The behavior of reentrant and triggered activity atrial rhythms may be quite similar  (<a class="graphic graphic_table graphicRef53347" href="/d/graphic/53347.html" rel="external">table 1</a>), and intracardiac recordings are usually necessary to make the diagnosis with certainty. The following criteria have been used to help identify the type of arrhythmia:</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial tachycardia has conventionally been called reentry when the arrhythmia is abrupt in onset and termination and can be started or stopped by spontaneous or programmed premature beats. However, triggered activity can show the same features [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A response to <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> has been thought to be quite specific for atrial tachycardias due to cyclic AMP-mediated triggered activity and to enhanced automaticity. In several small cohort studies, adenosine was ineffective in terminating IART [<a href="#rid18">18-20</a>]. Although some studies have provided conflicting data [<a href="#rid17">17,21,22</a>], the criteria used to define macroreentry did not exclude triggered activity as the cause of the arrhythmia [<a href="#rid19">19</a>]. </p><p></p><p>In comparison to the atrial abnormalities, conduction through the AV node, the specialized infranodal conduction system (His bundle, fascicles and bundle branches, terminal Purkinje fibers), and the ventricles is not directly impaired in intraatrial reentrant tachycardia. Thus, the QRS pattern and duration should not be abnormal unless the rapid rate causes some type of functional conduction disturbance.</p><p>Dual-loop figure-8 intraatrial reentry has been described that electrocardiographically mimics atrial flutter [<a href="#rid23">23</a>]. All such patients had undergone surgery for ostium secundum atrial septal defect (ASD) closure. The arrhythmias were quite resistant to antiarrhythmic therapy, and ablation of both loops may be required. This mechanism should be kept in mind in patients with corrected secundum ASD surgery.</p><p class="headingAnchor" id="H13989360"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis for intraatrial reentrant tachycardia (IART) is similar to that for other narrow QRS complex tachycardias (assuming there is normal AV conduction without bundle branch block) and includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial flutter</p><p class="bulletIndent1"><span class="glyph">●</span>Atrioventricular reciprocating tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Focal atrial tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Sinoatrial nodal reentrant tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus tachycardia, including inappropriate sinus tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Atrioventricular nodal reentrant tachycardia</p><p></p><p>A more in-depth discussion of the differential diagnosis of narrow QRS complex tachycardias is presented separately. </p><p class="headingAnchor" id="H4"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>While intraatrial reentrant tachycardia (IART) can be transient and asymptomatic, persistent and/or symptomatic IART requires treatment to relieve symptoms and to prevent long-term sequelae such as tachycardia-mediated cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p>Efforts to acutely terminate IART should begin with vagal maneuvers. If vagal maneuvers are unsuccessful, intravenous <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> can be administered. Catheter ablation of IART is generally the treatment of choice for chronic management of this arrhythmia, given its efficacy combined with the relatively poor efficacy of pharmacologic therapy.</p><p class="headingAnchor" id="H4694418"><span class="h2">Acute termination</span></p><p class="headingAnchor" id="H4694500"><span class="h3">Autonomic maneuvers</span><span class="headingEndMark"> — </span>The autonomic innervation of the atria is less than that of the specialized myocardial areas which comprise the sinoatrial and atrioventricular nodes. Thus, vagal stimulation has a variable and often negligible effect on reentrant intraatrial rhythms. However, it has been estimated that this arrhythmia can be terminated by carotid sinus massage in approximately one-fourth of cases, particularly those arising in the right atrium [<a href="#rid6">6</a>].</p><p>As such, for the acute termination of symptomatic IART, we suggest carotid sinus massage or another vagal maneuver as the initial therapy. (See  <a class="medical medical_review" href="/d/html/1034.html" rel="external">"Vagal maneuvers"</a>.)</p><p class="headingAnchor" id="H4694545"><span class="h3">IV adenosine and verapamil</span><span class="headingEndMark"> — </span>Although there is controversy as to the specificity and efficacy of calcium channel blockers, both <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> have been reported to be effective in 30 to 50 percent or more of cases [<a href="#rid17">17,18,21,24</a>]. For symptomatic IART that is persistent in spite of vagal maneuvers, we suggest using adenosine via intravenous push for acute termination of the arrhythmia. (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Intravenous adenosine'</a>.)</p><p>If <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> is unsuccessful and symptomatic IART persists, we then use intravenous <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>. We typically give a 5 to 10 mg IV bolus over two minutes; if no response, an additional 10 mg IV bolus may be administered 15 to 30 minutes following the initial dose. </p><p class="headingAnchor" id="H4694425"><span class="h2">Chronic therapy</span><span class="headingEndMark"> — </span>Few studies have been published regarding chronic pharmacologic therapy in IART, which appears limited in many cases by lack of efficacy and drug toxicity [<a href="#rid15">15</a>]. Catheter ablation, however, has relatively high success rates for the acute termination of IART and for the long-term prevention of recurrences.</p><p class="headingAnchor" id="H7"><span class="h3">Catheter ablation</span><span class="headingEndMark"> — </span>For IART that is symptomatic or persistent, thereby requiring long-term preventive therapy, we suggest catheter ablation as initial therapy rather than treatment with an antiarrhythmic agent. This is particularly true in younger patients who might be subject to the long-term side effect of years or decades of antiarrhythmic therapy.</p><p>Catheter ablation of macroreentrant atrial arrhythmias, including IART, has become the preferred treatment modality, with rates of acute success in terminating IART exceeding 80 percent in several cohort studies [<a href="#rid25">25-28</a>]. However, ablation does require specialized expertise and background knowledge of the predisposing factors. Electroanatomic mapping (EAD) and irrigated tipped catheters have further improved the outcomes after these ablations [<a href="#rid28">28-31</a>].</p><p>Excitable gaps are critical for all reentrant arrhythmias. An excitable gap allows a reentrant arrhythmia to be entrained, and if entrainment is achieved with concealed conduction, the critical pathway is identified. This feature is used therapeutically when overdrive atrial pacing is employed to terminate these arrhythmias. This was employed in the management of IART complicating surgically corrected transposition of the great arteries. The problem was that if it fails or if overdrive pacing accelerates the heart rate, it may lead to hemodynamic compromise and, in turn, death [<a href="#rid32">32</a>].</p><p>Since an excitable gap is usually present in IART, a PAC or atrial pacing can usually cause a beat to be inserted in the reentrant pathway, thereby terminating the arrhythmia [<a href="#rid25">25,26</a>]. Radiofrequency catheter ablation is extremely effective in patients with recurrent arrhythmias and has largely replaced chronic pacemaker therapy or surgery  (<a class="graphic graphic_waveform graphicRef58120 graphicRef50219 graphicRef82052" href="/d/graphic/58120.html" rel="external">waveform 2A-C</a>) [<a href="#rid6">6,25-27</a>].</p><p>Intraatrial reentrant tachycardia is common after surgery for congenital heart disease. Radiofrequency ablation is successful, but the recurrence rate is high [<a href="#rid33">33-37</a>]. The reentrant circuit for intraatrial reentrant tachycardia often involves the tricuspid valve isthmus following the Mustard/Senning procedure and in other types of repaired congenital heart disease [<a href="#rid37">37</a>]. The circuits in patients after the Fontan procedures differ, with the lateral right atrial wall being the more common area for successful radiofrequency ablation [<a href="#rid37">37</a>].</p><p>Ablation or pacing for typical atrial flutter may give rise to macroreentrant tachycardias arising in the right atrium, with such arrhythmias occurring more frequently as the use of ablation and devices becomes more common. The term "lower loop reentry" has been used to describe counterclockwise reentry around the inferior vena cava where the anterior portion of the reentrant circuit is the IVC-tricuspid valve isthmus and the posterior arm is the low posterior right atrial wall across the crista terminalis, making it a variant of typical atrial flutter in which the superior pivot point is lower [<a href="#rid38">38</a>]. At other times, circuits may involve the free wall of the right atrium. The ECG usually shows negative atrial deflections in the inferior leads [<a href="#rid39">39</a>].</p><p>EAD has proven useful in ablating right macro-reentrant tachycardias including IART, particularly when the mid-diastolically activated isthmus can be identified [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies", section on 'Mapping and ablation'</a>.)</p><p class="headingAnchor" id="H4694652"><span class="h3">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Available pharmacologic options for the prevention of IART include calcium channel blockers, sodium channel blockers, beta blockers, and <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, all of which have been tried with some success at preventing IART recurrences. However, many patients with IART have structural heart disease, which limits the choice of available antiarrhythmic agents. If IART cannot be prevented, rate control can be attempted with non-dihydropyridine calcium channel blockers or beta adrenergic blockers.</p><p>For chronic therapy of IART when ablation is not an option or has been unsuccessful in preventing recurrent IART, we suggest <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> as first-line therapy rather than a beta blocker or antiarrhythmic agent. This suggestion is based on the efficacy of verapamil in the acute termination of IART in addition to it generally being well-tolerated [<a href="#rid24">24</a>]. Beta blockers are also effective in some cases but have a larger spectrum of side effects. The use of calcium channel modulators, particularly class IC antiarrhythmic drugs  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 2</a>) such as <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a> and <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a>, is limited by major toxicities and proarrhythmic actions, especially in patients with coronary artery disease. </p><p class="headingAnchor" id="H4694829"><span class="h3">Permanent pacemaker insertion</span><span class="headingEndMark"> — </span>In rare circumstances, such as when IART persists following an unsuccessful ablation and standard pharmacologic therapy, insertion of a permanent pacemaker may be considered. Pacemaker insertion allows for the more aggressive use of rate controlling medications, especially in patients with sinus node dysfunction. (See  <a class="medical medical_review" href="/d/html/1072.html" rel="external">"Sinus node dysfunction: Treatment"</a>.)</p><p>Pacemakers with anti-tachycardia features have been used to successfully terminate IART but have been associated with sudden death [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H2456745"><span class="h2">Our approach to treatment</span><span class="headingEndMark"> — </span>Based on the available evidence, we take the following approach to treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>For the acute termination of symptomatic IART, we suggest carotid sinus massage or another vagal maneuver as the initial therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For symptomatic IART that is persistent in spite of vagal maneuvers, we suggest using <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> via intravenous push rather than <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> for acute termination of the arrhythmia. If adenosine is unsuccessful and symptomatic IART persists, we then use intravenous verapamil.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For IART that is symptomatic or persistent, thereby requiring long-term preventive therapy, we suggest catheter ablation as initial therapy rather than treatment with an antiarrhythmic agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For chronic therapy of IART when ablation is not an option or has been unsuccessful in preventing recurrent IART, we suggest <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> as first-line therapy rather than a beta blocker or antiarrhythmic agent. If verapamil is unsuccessful or not tolerated, beta blockers or antiarrhythmic agents can be used.</p><p></p><p class="headingAnchor" id="H1473793905"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H4694871"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and clinical setting</strong> – Intraatrial reentrant tachycardia (IART) refers to any macroreentrant atrial tachycardia that does not utilize the cavotricuspid isthmus  (<a class="graphic graphic_figure graphicRef52904" href="/d/graphic/52904.html" rel="external">figure 1</a>) as a critical pathway for the reentry to perpetuate. IART generally occurs in one of three settings: post-surgical repair of congenital heart disease, post-surgical scar (incisional tachycardia), or post-catheter-based or surgical management of atrial fibrillation, although it has also been reported in the absence of surgical or catheter intervention. (See <a class="local">'Definition, prevalence, and mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism</strong> – IART, which is responsible for approximately 6 percent of atrial tachycardias in patients referred for electrophysiologic studies, has a different activation sequence of atrial depolarization, leading to a P wave morphology that differs from that of normal sinus rhythm. IART most often begins with a PAC and is perpetuated via a reentry circuit  (<a class="graphic graphic_figure graphicRef82249" href="/d/graphic/82249.html" rel="external">figure 2</a>). (See <a class="local">'Definition, prevalence, and mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations and significance of IART are variable, depending upon the hemodynamic effects of the increase in heart rate and the heart rate achieved. Some patients are asymptomatic, while others have symptoms that range from palpitations and lightheadedness to, in rare cases, syncope. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiographic findings</strong> – During an arrhythmic episode, the electrocardiographic (ECG) findings in IART are similar to those of most other regular supraventricular tachycardias (SVT), with evidence of atrial activity (P waves) associated with ventricular activity (QRS complexes) in a 1:1 fashion. In the appropriate clinical setting (eg, prior cardiac surgery, prior ablation, etc), the surface ECG can be highly suggestive of IART. However, the surface ECG alone cannot reliably distinguish between IART and other types of SVT, most notably focal atrial tachycardia. Because the surface electrocardiogram alone is not reliable in distinguishing IART from other types of SVT, invasive electrophysiological studies (EPS) are employed to help make this distinction. (See <a class="local">'Electrocardiographic findings'</a> above and <a class="local">'Electrophysiological features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for intraatrial reentrant tachycardia (IART) is similar to that for other narrow QRS complex tachycardias (assuming there is normal AV conduction without bundle branch block). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – While intraatrial reentrant tachycardia (IART) can be transient and asymptomatic, persistent and/or symptomatic IART requires treatment to relieve symptoms and to prevent long-term sequelae such as tachycardia-mediated cardiomyopathy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute termination</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Autonomic maneuvers</strong> – For the acute termination of symptomatic IART, we suggest carotid sinus massage or another vagal maneuver as the initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Autonomic maneuvers'</a> above and  <a class="medical medical_review" href="/d/html/1034.html" rel="external">"Vagal maneuvers"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pharmacologic therapy</strong> – For symptomatic IART that is persistent in spite of vagal maneuvers, we suggest using <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> via intravenous push rather than <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> for acute termination of the arrhythmia (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If adenosine is unsuccessful and symptomatic IART persists, we then use intravenous verapamil. (See <a class="local">'IV adenosine and verapamil'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic therapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Catheter ablation as initial therapy</strong> – For IART that is symptomatic or persistent, thereby requiring long-term preventive therapy, we suggest catheter ablation as initial therapy rather than treatment with an antiarrhythmic agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Catheter ablation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pharmacologic therapy</strong> – For chronic therapy of IART when ablation is not an option or has been unsuccessful in preventing recurrent IART, we suggest <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> as first-line therapy rather than a beta blocker or antiarrhythmic agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If verapamil is unsuccessful or not tolerated, beta blockers or antiarrhythmic agents can be used. (See <a class="local">'Pharmacologic therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Saoudi N, Cosío F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1162.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2016; 13:e136.</a></li><li><a class="nounderline abstract_t">Kirsh JA, Walsh EP, Triedman JK. Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol 2002; 90:338.</a></li><li><a class="nounderline abstract_t">Chae S, Oral H, Good E, et al. Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence. J Am Coll Cardiol 2007; 50:1781.</a></li><li><a class="nounderline abstract_t">Fiala M, Chovancík J, Neuwirth R, et al. Atrial macroreentry tachycardia in patients without obvious structural heart disease or previous cardiac surgical or catheter intervention: characterization of arrhythmogenic substrates, reentry circuits, and results of catheter ablation. J Cardiovasc Electrophysiol 2007; 18:824.</a></li><li class="breakAll">Josephson ME. Supraventricular Tachycardias. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations, 4th, Lippincott, Williams, and Wilkins, Philadelphia 2008.</li><li><a class="nounderline abstract_t">Gillette PC. Supraventricular arrhythmias in children. J Am Coll Cardiol 1985; 5:122B.</a></li><li><a class="nounderline abstract_t">Gerstenfeld EP, Callans DJ, Dixit S, et al. Mechanisms of organized left atrial tachycardias occurring after pulmonary vein isolation. Circulation 2004; 110:1351.</a></li><li><a class="nounderline abstract_t">Deisenhofer I, Estner H, Zrenner B, et al. Left atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation: incidence, electrophysiological characteristics, and results of radiofrequency ablation. Europace 2006; 8:573.</a></li><li><a class="nounderline abstract_t">Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015; 372:1812.</a></li><li><a class="nounderline abstract_t">Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017; 14:e275.</a></li><li><a class="nounderline abstract_t">Wu D, Amat-y-leon F, Denes P, et al. Demonstration of sustained sinus and atrial re-entry as a mechanism of paroxysmal supraventricular tachycardia. Circulation 1975; 51:234.</a></li><li><a class="nounderline abstract_t">Josephson ME. Paroxysmal supraventricular tachycardia: an electrophysiologic approach. Am J Cardiol 1978; 41:1123.</a></li><li class="breakAll">Akhtar M. Supraventricular tachycardias. Electrophysiologic mechanisms, diagnosis and pharmacologic therapy. In: Tachycardias: Mechanisms, Diagnosis, Treatment, Josephson ME, Wellens HJJ (Eds), Lea &amp; Febiger, Philadelphia 1984. p.137.</li><li><a class="nounderline abstract_t">Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol 1985; 6:871.</a></li><li><a class="nounderline abstract_t">Medi C, Kalman JM. Prediction of the atrial flutter circuit location from the surface electrocardiogram. Europace 2008; 10:786.</a></li><li><a class="nounderline abstract_t">Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation 1994; 90:1262.</a></li><li><a class="nounderline abstract_t">Engelstein ED, Lippman N, Stein KM, Lerman BB. Mechanism-specific effects of adenosine on atrial tachycardia. Circulation 1994; 89:2645.</a></li><li><a class="nounderline abstract_t">Iwai S, Markowitz SM, Stein KM, et al. Response to adenosine differentiates focal from macroreentrant atrial tachycardia: validation using three-dimensional electroanatomic mapping. Circulation 2002; 106:2793.</a></li><li><a class="nounderline abstract_t">Markowitz SM, Nemirovksy D, Stein KM, et al. Adenosine-insensitive focal atrial tachycardia: evidence for de novo micro-re-entry in the human atrium. J Am Coll Cardiol 2007; 49:1324.</a></li><li><a class="nounderline abstract_t">Kall JG, Kopp D, Olshansky B, et al. Adenosine-sensitive atrial tachycardia. Pacing Clin Electrophysiol 1995; 18:300.</a></li><li><a class="nounderline abstract_t">Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999; 99:1034.</a></li><li><a class="nounderline abstract_t">Shah D, Jaïs P, Takahashi A, et al. Dual-loop intra-atrial reentry in humans. Circulation 2000; 101:631.</a></li><li><a class="nounderline abstract_t">Garratt C, Linker N, Griffith M, et al. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am J Cardiol 1989; 64:1310.</a></li><li><a class="nounderline abstract_t">Kay GN, Chong F, Epstein AE, et al. Radiofrequency ablation for treatment of primary atrial tachycardias. J Am Coll Cardiol 1993; 21:901.</a></li><li><a class="nounderline abstract_t">Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation 1994; 89:1074.</a></li><li><a class="nounderline abstract_t">Baker BM, Lindsay BD, Bromberg BI, et al. Catheter ablation of clinical intraatrial reentrant tachycardias resulting from previous atrial surgery: localizing and transecting the critical isthmus. J Am Coll Cardiol 1996; 28:411.</a></li><li><a class="nounderline abstract_t">Delacretaz E, Ganz LI, Soejima K, et al. Multi atrial maco-re-entry circuits in adults with repaired congenital heart disease: entrainment mapping combined with three-dimensional electroanatomic mapping. J Am Coll Cardiol 2001; 37:1665.</a></li><li><a class="nounderline abstract_t">Jaïs P, Shah DC, Haïssaguerre M, et al. Prospective randomized comparison of irrigated-tip versus conventional-tip catheters for ablation of common flutter. Circulation 2000; 101:772.</a></li><li><a class="nounderline abstract_t">Triedman JK, Alexander ME, Berul CI, et al. Electroanatomic mapping of entrained and exit zones in patients with repaired congenital heart disease and intra-atrial reentrant tachycardia. Circulation 2001; 103:2060.</a></li><li><a class="nounderline abstract_t">Triedman JK, Alexander ME, Love BA, et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol 2002; 39:1827.</a></li><li><a class="nounderline abstract_t">Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol 2003; 92:871.</a></li><li><a class="nounderline abstract_t">Triedman JK, Saul JP, Weindling SN, Walsh EP. Radiofrequency ablation of intra-atrial reentrant tachycardia after surgical palliation of congenital heart disease. Circulation 1995; 91:707.</a></li><li><a class="nounderline abstract_t">Van Hare GF, Lesh MD, Ross BA, et al. Mapping and radiofrequency ablation of intraatrial reentrant tachycardia after the Senning or Mustard procedure for transposition ofthe great arteries. Am J Cardiol 1996; 77:985.</a></li><li><a class="nounderline abstract_t">Triedman JK, Bergau DM, Saul JP, et al. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol 1997; 30:1032.</a></li><li><a class="nounderline abstract_t">Dorostkar PC, Cheng J, Scheinman MM. Electroanatomical mapping and ablation of the substrate supporting intraatrial reentrant tachycardia after palliation for complex congenital heart disease. Pacing Clin Electrophysiol 1998; 21:1810.</a></li><li><a class="nounderline abstract_t">Collins KK, Love BA, Walsh EP, et al. Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant tachycardia in patients with congenital heart disease. Am J Cardiol 2000; 86:969.</a></li><li><a class="nounderline abstract_t">Cheng J, Cabeen WR Jr, Scheinman MM. Right atrial flutter due to lower loop reentry: mechanism and anatomic substrates. Circulation 1999; 99:1700.</a></li><li><a class="nounderline abstract_t">Kall JG, Rubenstein DS, Kopp DE, et al. Atypical atrial flutter originating in the right atrial free wall. Circulation 2000; 101:270.</a></li><li><a class="nounderline abstract_t">DePonti, R, Verlato, et al. Treatment of macro-re-entrant atrial tachycardia based on electroanatomic mapping: Identification and ablation of the mid-diastolic isthmus. Europace 2007; 9:499.</a></li><li><a class="nounderline abstract_t">Rhodes LA, Walsh EP, Gamble WJ, et al. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol 1995; 18:1005.</a></li></ol></div><div id="topicVersionRevision">Topic 937 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11440490" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409100" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12127629" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17964043" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17537207" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Atrial macroreentry tachycardia in patients without obvious structural heart disease or previous cardiac surgical or catheter intervention: characterization of arrhythmogenic substrates, reentry circuits, and results of catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17537207" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Atrial macroreentry tachycardia in patients without obvious structural heart disease or previous cardiac surgical or catheter intervention: characterization of arrhythmogenic substrates, reentry circuits, and results of catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3889104" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Supraventricular arrhythmias in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15353501" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mechanisms of organized left atrial tachycardias occurring after pulmonary vein isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864612" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Left atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation: incidence, electrophysiological characteristics, and results of radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946280" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Approaches to catheter ablation for persistent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28506916" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1112003" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Demonstration of sustained sinus and atrial re-entry as a mechanism of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/665519" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Paroxysmal supraventricular tachycardia: an electrophysiologic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/665519" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Paroxysmal supraventricular tachycardia: an electrophysiologic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4031302" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Atrial flutter in the young: a collaborative study of 380 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456647" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prediction of the atrial flutter circuit location from the surface electrocardiogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087935" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205677" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mechanism-specific effects of adenosine on atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451005" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Response to adenosine differentiates focal from macroreentrant atrial tachycardia: validation using three-dimensional electroanatomic mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394965" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adenosine-insensitive focal atrial tachycardia: evidence for de novo micro-re-entry in the human atrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731878" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Adenosine-sensitive atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051297" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Electrophysiologic effects of adenosine in patients with supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673255" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dual-loop intra-atrial reentry in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589197" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450158" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Radiofrequency ablation for treatment of primary atrial tachycardias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8124793" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800118" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Catheter ablation of clinical intraatrial reentrant tachycardias resulting from previous atrial surgery: localizing and transecting the critical isthmus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11345382" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multi atrial maco-re-entry circuits in adults with repaired congenital heart disease: entrainment mapping combined with three-dimensional electroanatomic mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10683351" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prospective randomized comparison of irrigated-tip versus conventional-tip catheters for ablation of common flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319195" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Electroanatomic mapping of entrained and exit zones in patients with repaired congenital heart disease and intra-atrial reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12039499" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516898" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7828297" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Radiofrequency ablation of intra-atrial reentrant tachycardia after surgical palliation of congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644650" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mapping and radiofrequency ablation of intraatrial reentrant tachycardia after the Senning or Mustard procedure for transposition ofthe great arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316535" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9744447" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Electroanatomical mapping and ablation of the substrate supporting intraatrial reentrant tachycardia after palliation for complex congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053709" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant tachycardia in patients with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190879" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Right atrial flutter due to lower loop reentry: mechanism and anatomic substrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10645923" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Atypical atrial flutter originating in the right atrial free wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17478460" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of macro-re-entrant atrial tachycardia based on electroanatomic mapping: Identification and ablation of the mid-diastolic isthmus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7659551" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
